This profile describes access and programme structure. Inclusion is not an endorsement, regulatory finding, or clinical recommendation. Prescription decisions belong to a qualified prescriber.
At a glance
Pricing, medicine, location, care, fulfilment, funding, and policy claims are separated below.
An open check means the public sources were not specific enough—not that the service failed the check.
Resumen en español
OrderlyMeds para usuarios hispanohablantes
Esta sección ofrece una orientación breve en español sobre el perfil estadounidense. La investigación completa de precios, acceso, farmacia y seguimiento permanece arriba mientras ampliamos la revisión editorial en español.
No encontramos una fuente primaria suficientemente específica para afirmar que una cita clínica esté disponible en español. Confirma el idioma y cualquier servicio de interpretación antes de pagar.
- si la cita concreta será en español;
- el coste mensual ordinario y qué incluye;
- la licencia estatal del profesional;
- el medicamento, la farmacia y el coste por separado.
Esta traducción editorial no demuestra que el proveedor ofrezca atención clínica en español y no sustituye una valoración médica.
Comparar proveedores para hispanohablantes en EE. UU. →How the program is structured
A direct-pay compounded program whose public pricing distinguishes a prepaid two-month starter offer from the normal monthly rate. The advertised fee bundles telehealth, medication, supplies, and shipping, but the named pharmacy and state-product mapping are not public in one table.
GLP.directory checked the cited public sources on Sep 13, 2026. We reviewed published access, cost, care, fulfilment, funding, cancellation, monitoring, and switching details; we have not audited individual clinical encounters, prescriptions, pharmacy operations, or outcomes.
Availability can change by state, clinician, medical history, product, pharmacy, inventory, and insurance plan. “Not publicly confirmed” means we did not find a sufficiently specific answer in the cited public material. Confirm the current patient-specific answer before paying or changing care.
Service configuration
These structured fields power the directory filters. They describe the reviewed public route and should be reconfirmed for the selected plan.
- Provider type
- Telehealth program
- Medicine context
- Semaglutide (Wegovy; Ozempic/Rybelsus for type 2 diabetes) · Tirzepatide (Zepbound; Mounjaro for type 2 diabetes)
- Formats reviewed
- Injection
- Funding routes
- Private pay
- Service features
- Clinician support · Switching pathway · Home delivery
- Access check
- Confirm current state access
- Evidence status
- Primary sources reviewed
- Research depth
- 2 cited sources · 2 medicine rows · 4 open checks
Recurring cost breakdown
- Compounded semaglutide: $149 for a two-month starter offer, then $149/month at the review date.
- Compounded tirzepatide: $299 for a two-month starter offer, then $299/month at the review date.
- No separate membership fee is advertised for these plans.
- Medication, clinician review, supplies, and shipping are presented as bundled; verify taxes, term, and current-dose pricing at checkout.
- Medicine + dose
- Membership or consultation
- Delivery + supplies
- Labs + follow-up
- Renewal after offers
Medication and formulation matrix
| Medication | Form | Regulatory / program path | Published price view |
|---|---|---|---|
| Compounded semaglutide | Weekly injection | Not FDA-approved | $149/2-month starter; $149/month thereafter |
| Compounded tirzepatide | Weekly injection | Not FDA-approved | $299/2-month starter; $299/month thereafter |
Important: “Compounded” means the product is not FDA approved. A brand approved for one condition is not automatically approved for another. The treating clinician determines whether any prescription is appropriate.
State-by-state availability
- Multi-state telehealth access is advertised, with product availability subject to state rules.
- A single current state-by-formulation table was not available in the reviewed public pages.
Clinician access and follow-up cadence
- Online medical intake and clinician review precede fulfillment.
- The workflow emphasizes asynchronous contact; confirm availability and response time for live clinical questions.
Pharmacy and fulfillment
- OrderlyMeds uses pharmacy partners and ships prescribed medication to the patient.
- The specific dispenser can change by state and was not named in the reviewed pricing result.
Insurance and prior authorization
- The reviewed plans are cash pay and do not depend on insurance approval.
- HSA/FSA eligibility, reimbursement documentation, and plan acceptance should be confirmed separately.
Cancellation, refund, and commitment
- Starter and monthly plans can carry different cancellation timing because the starter supply is prepaid.
- Public cancellation/refund terms should be checked immediately before purchase, particularly once a prescription reaches the pharmacy.
Labs, monitoring, and dose management
- No universal included lab panel was confirmed from the public pricing page.
- A clinician may request information or testing based on history.
Maintenance and switching
- Returning/current-dose offers can differ from new-customer starter pricing.
- Confirm whether an established dose will be continued and when the next refill form must be completed.
Program snapshot
All-in cash-pay program
Profiled support: Ongoing clinician access, Simplified intake and fulfillment.
Cash pay
The reviewed program is positioned as cash pay.
Verify before purchase
OrderlyMeds uses pharmacy partners; confirm which pharmacy will dispense your prescription and whether it changes by state.
What the advertised program may include
- Online clinician review
- Medication when prescribed
- Supplies and shipping as advertised
- Provider access
Useful comparison signals
Based on the provider’s published program structure, this profile is tagged for the following searches. These are filters, not endorsements or clinical recommendations.
- Starting care and comparing first-provider requirements
- Switching providers or continuing an established treatment
- Comparing lower-cost access routes and recurring totals
- Ongoing clinician access
- Simplified intake and fulfillment
Open evidence gaps
These are material details we could not confirm precisely enough from the cited public pages. They are the highest-priority questions to resolve directly.
- Named pharmacy
- Full state-by-product matrix
- Published live-visit cadence
- Universal lab protocol
Questions to ask before paying
- What is the ordinary recurring total after any introductory period?
- Does that total include clinician care, medication, supplies, labs, and shipping?
- Which clinician group and dispensing pharmacy will be responsible for my care?
- What happens to billing if I am not prescribed the advertised treatment?
- What records and timing do you require if I am switching from another provider?
Source ledger
Every entry below is a provider-controlled or official public source. A source link documents what was published; it does not independently validate performance, regulatory compliance, safety, or outcomes.
Starter versus ongoing price, formulations and included-service claims
Care and fulfillment model